Corporate News

2023

Featured at 2023 ATS Respiratory Innovation Summit

May 3, 2023, 16:29 by vivienne.seymour

Polarean also exhibiting at 2023 American Thoracic Society annual meeting, providing a great opportunity to showcase XENOVIEW technology to other pulmonary care innovators and providers

Polarean Imaging plc (AIM: POLX), the medical imaging technology company, has been selected as one of the featured companies as a poster presenter at the American Thoracic Society's ("ATS") 2023 Respiratory Innovation Summit ("RIS"), taking place 19-20 May in Washington D.C.

The Respiratory Innovation Summit unites innovators, investors, clinicians, and advocacy groups who work in the field of pulmonary medicine. The meeting historically attracts more than 275 global leaders representing all facets of the respiratory industry, including start-ups, venture capital, government, academia, and clinicians.

In addition to Polarean being selected as a featured company, Bastiaan Driehuys, PhD, Polarean's Chief Scientific Officer, will speak on lung imaging as a panel member in the "Biomarkers and Innovation" session taking place in the afternoon of 20 May at RIS.

Following the Respiratory Innovation Summit, Polarean will be exhibiting at the 2023 ATS International Conference, taking place 21-24 May. Polarean team members, including Bastiaan Driehuys, PhD (Chief Scientific Officer), and Alex Dusek (Chief Commercial Officer) will be onsite to provide information on the technology and also for networking.  Polarean can be found at booth # 2137.

The ATS International Conference connects specialists in all aspects of respiratory health - from clinicians to researchers to educators, all of whom share a passion for improving patient care. The conference showcases the latest advances and discoveries in respiratory science, patient care, and global public health.

Richard Hullihen, CEO of Polarean, said: "The Respiratory Innovation Summit and the American Thoracic Society's annual conference provide a great venue to showcase  XENOVIEW and the Xe MRI platform with individuals interested in the opportunities to collaborate. By creating greater awareness of our Xe MRI platform amongst clinicians, regulators, investors, and potential pharma industry partners, these events will be another step in advancing our commercialization strategy by growing awareness and interest in the different ways that our technology can move pulmonary care forward."

Additionally, at ATS numerous clinicians and scientists will be presenting on various research applications of Xe MRI.  A listing of these presentations, their title, author, and session time is available below.

Enquiries:

Polarean Imaging plc 

www.polarean.com / www.polarean-ir.com  

 Richard Hullihen, Chief Executive Officer 

Via Walbrook PR 

 Kenneth West, Chairman 




 Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker) 

+44 (0)20 7710 7600 

 Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking) 


 Nick Adams / Nick Harland (Corporate Broking) 



 Walbrook PR 

Tel: +44 (0)20 7933 8780 or [email protected]  

 Anna Dunphy / Phillip Marriage  

Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082 

RLF Communications (US media enquiries)
Michelle Rash

[email protected]
336-823-5501









About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical imaging technology companies operating in the high-resolution medical imaging space. Polarean aspires to revolutionize pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community in need of new solutions to evaluate lung ventilation, diagnose disease, characterize disease progression, and monitor response to treatment. By researching, developing, and commercializing novel imaging solutions with a non-invasive and radiation-free functional imaging platform. Polarean's vision is to help address the global unmet medical needs of more than 500 million patients worldwide suffering with chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized MRI contrast agent to be approved in the United States. On Dec. 23, 2022, the FDA granted approval for Polarean's first drug device combination product, XENOVIEWTM (Xenon Xe129 hyperpolarized). Xe129 MRI is also currently being studied for visualization and quantification of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream for future clinical indications.

About The American Thoracic Society (www.thoracic.org)

The American Thoracic Society (ATS) improves global health by advancing research, patient care, and public health in pulmonary disease, critical illness, and sleep disorders. Founded in 1905 to combat TB, the ATS has grown to tackle asthma, COPD, lung cancer, sepsis, acute respiratory distress, and sleep apnea, among other diseases.

XENOVIEW IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold.

Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated.

Adverse Reactions

Adverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness.  Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarized xenon Xe 129 administration. XENOVIEW is not approved for use in pediatric patients less than 12 years of age.

Please see full prescribing information at www.xenoview.net

 

ATS Abstract Title


  Presentation Date


 Abstract  Number


 Session and Location


129Xe Gas-exchange MRI and CT Pulmonary Vascular Abnormalities in GINA 4-5 Asthma

May 21, 2023

09:00 - 11:00

A 1043

Mini Symposium A17.

 

Tell me What You See: New Studies In Lung Imaging

 

Walter E. Washington Convention Center, Room 204 A-C (Level 2)

 

Hyperpolarized 129Xe MRI Visualizes Lung Function Impairment in Suspected Inflammatory Interstitial Lung Disease

May 21, 2023

09:00 - 11:00

A 1044

Mini Symposium A17.

 

Tell me What You See: New Studies In Lung Imaging

 

Walter E. Washington Convention Center, Room 204 A-C (Level 2)

 

Dynamic Changes in Hyperpolarized 129Xe MRI Measures After Initiation of Therapy in Patients With Idiopathic Pulmonary Fibrosis Associate With Lung Function

 

 

May 21, 2023

Poster Viewing Time

09:00 - 09:45

Poster Discussion Time

09:45 - 11:00

 

823

Poster Discussion Session. A23.

 

LEVERAGING IMAGING AND BIOSAMPLES TO IMPROVE DIAGNOSIS AND RISK PREDICTION IN ILA AND ILD

 

Walter E. Washington Convention Center, Room 209 A-C (Level2)

Dynamic 129Xe-Hyperpolarized MRI for Non-invasive Evaluation of Regional Lung Ventilation in Thoracic Insufficiency Syndrome

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P508

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Retrospective Cardiopulmonary Gating of Free-breathing Hyperpolarized Xenon-129 Spectroscopy

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P511

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Assessing Unilateral Lung Transplantation With Dynamic Hyperpolarized Xenon-129

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P512

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Uneven Respiratory Function Observed With Dynamic Hyperpolarized Xenon-129 MRI in a Pig Thoracic Insufficiency Syndrome Model

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P513

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Feasibility of 3D Dynamic Gas- and Dissolved-Phase Imaging of the Rodent Lung Using Hyperpolarized 129Xe Magnetic Resonance Imaging

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P527

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Lung Structure-function in Pediatric Survivors of Congenital Diaphragmatic Hernia

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P528

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Measuring Lung Function With Inversion Instead of Saturation Recovery Hyperpolarized Xenon-129 MR Spectroscopy

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P529

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Minimal Clinically Important Difference for 129Xe MRI Ventilation Defect Percent in Patients With Asthma

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P538

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Hyperpolarized 129Xe Ventilation and Gas Exchange MRI in Young Adults With Cystic Fibrosis

May 21, 2023

Poster Viewing Time

11:30 - 13:15

P539

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Hyperpolarized 129-Xenon Magnetic Resonance Imaging (MRI) Ventilation Mapping in Pediatric COVID-19 Survivors

May 22, 2023

Poster Viewing Time

09:00 - 09:45

Poster Discussion Time

09:45 - 11:00

 

206

RAPiD: Rapid Abstract Poster Discussion Session. B27.

 

EVOLVING CONCEPTS IN LUNG FUNCTION TESTING AND MONITORING

 

Walter E. Washington Convention Center, Room 103 A-B (Street Level)

Tracking Regional Changes in CF Lung Disease After 1 Day of Airway-clearance Withdrawal, Using UTE and Xe MRI

May 23, 2023

Poster Viewing Time

14:15 - 15:00

Poster Discussion Time

15:00 - 16:15

 


Poster Discussion Session. C106.

 

OUT OF THE 'MUC': UPDATES IN PCD AND CF

 

Marriott Marquis Washington, Marquis Ballroom, Salons 3-4 (Level M2)

129Xe Magnetic Resonance Imaging-based Phenotypes of Long COVID: A Multi-center Evaluation

 May 24, 2023

Poster Viewing Time

12:00 - 12:45

Poster Discussion Time

12:45 - 14:00

 

602

Poster Discussion Session. D109.

 

THE LONG AND THE SHORT OF LONG COVID

 

Walter E. Washington Convention Center, Room 201 (Level 2) 

Post-acute COVID-19 Imaging Abnormalities on Hyperpolarized 129Xe MRI Persist Over 6 Months

May 24, 2023

Poster Viewing Time

12:00 - 12:45

Poster Discussion Time

12:45 - 14:00

 

610

Poster Discussion Session. D109.

 

THE LONG AND THE SHORT OF LONG COVID

 

Walter E. Washington Convention Center, Room 201 (Level 2)

 

Assessment of Gas Exchange in Long COVID Using Hyperpolarized 129-Xenon MRI and Dual Energy CT

May 23, 2023

Poster Viewing Time

12:00 - 12:45

Poster Discussion Time

12:45 - 14:00

 

611

Poster Discussion Session. D109.

 

THE LONG AND THE SHORT OF LONG COVID

 

Walter E. Washington Convention Center, Room 201 (Level 2)

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

Load more comments
Comment by from

2022

Featured at 2023 ATS Respiratory Innovation Summit

May 3, 2023, 16:29 by vivienne.seymour

Polarean also exhibiting at 2023 American Thoracic Society annual meeting, providing a great opportunity to showcase XENOVIEW technology to other pulmonary care innovators and providers

Polarean Imaging plc (AIM: POLX), the medical imaging technology company, has been selected as one of the featured companies as a poster presenter at the American Thoracic Society's ("ATS") 2023 Respiratory Innovation Summit ("RIS"), taking place 19-20 May in Washington D.C.

The Respiratory Innovation Summit unites innovators, investors, clinicians, and advocacy groups who work in the field of pulmonary medicine. The meeting historically attracts more than 275 global leaders representing all facets of the respiratory industry, including start-ups, venture capital, government, academia, and clinicians.

In addition to Polarean being selected as a featured company, Bastiaan Driehuys, PhD, Polarean's Chief Scientific Officer, will speak on lung imaging as a panel member in the "Biomarkers and Innovation" session taking place in the afternoon of 20 May at RIS.

Following the Respiratory Innovation Summit, Polarean will be exhibiting at the 2023 ATS International Conference, taking place 21-24 May. Polarean team members, including Bastiaan Driehuys, PhD (Chief Scientific Officer), and Alex Dusek (Chief Commercial Officer) will be onsite to provide information on the technology and also for networking.  Polarean can be found at booth # 2137.

The ATS International Conference connects specialists in all aspects of respiratory health - from clinicians to researchers to educators, all of whom share a passion for improving patient care. The conference showcases the latest advances and discoveries in respiratory science, patient care, and global public health.

Richard Hullihen, CEO of Polarean, said: "The Respiratory Innovation Summit and the American Thoracic Society's annual conference provide a great venue to showcase  XENOVIEW and the Xe MRI platform with individuals interested in the opportunities to collaborate. By creating greater awareness of our Xe MRI platform amongst clinicians, regulators, investors, and potential pharma industry partners, these events will be another step in advancing our commercialization strategy by growing awareness and interest in the different ways that our technology can move pulmonary care forward."

Additionally, at ATS numerous clinicians and scientists will be presenting on various research applications of Xe MRI.  A listing of these presentations, their title, author, and session time is available below.

Enquiries:

Polarean Imaging plc 

www.polarean.com / www.polarean-ir.com  

 Richard Hullihen, Chief Executive Officer 

Via Walbrook PR 

 Kenneth West, Chairman 




 Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker) 

+44 (0)20 7710 7600 

 Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking) 


 Nick Adams / Nick Harland (Corporate Broking) 



 Walbrook PR 

Tel: +44 (0)20 7933 8780 or [email protected]  

 Anna Dunphy / Phillip Marriage  

Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082 

RLF Communications (US media enquiries)
Michelle Rash

[email protected]
336-823-5501









About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical imaging technology companies operating in the high-resolution medical imaging space. Polarean aspires to revolutionize pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community in need of new solutions to evaluate lung ventilation, diagnose disease, characterize disease progression, and monitor response to treatment. By researching, developing, and commercializing novel imaging solutions with a non-invasive and radiation-free functional imaging platform. Polarean's vision is to help address the global unmet medical needs of more than 500 million patients worldwide suffering with chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized MRI contrast agent to be approved in the United States. On Dec. 23, 2022, the FDA granted approval for Polarean's first drug device combination product, XENOVIEWTM (Xenon Xe129 hyperpolarized). Xe129 MRI is also currently being studied for visualization and quantification of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream for future clinical indications.

About The American Thoracic Society (www.thoracic.org)

The American Thoracic Society (ATS) improves global health by advancing research, patient care, and public health in pulmonary disease, critical illness, and sleep disorders. Founded in 1905 to combat TB, the ATS has grown to tackle asthma, COPD, lung cancer, sepsis, acute respiratory distress, and sleep apnea, among other diseases.

XENOVIEW IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold.

Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated.

Adverse Reactions

Adverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness.  Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarized xenon Xe 129 administration. XENOVIEW is not approved for use in pediatric patients less than 12 years of age.

Please see full prescribing information at www.xenoview.net

 

ATS Abstract Title


  Presentation Date


 Abstract  Number


 Session and Location


129Xe Gas-exchange MRI and CT Pulmonary Vascular Abnormalities in GINA 4-5 Asthma

May 21, 2023

09:00 - 11:00

A 1043

Mini Symposium A17.

 

Tell me What You See: New Studies In Lung Imaging

 

Walter E. Washington Convention Center, Room 204 A-C (Level 2)

 

Hyperpolarized 129Xe MRI Visualizes Lung Function Impairment in Suspected Inflammatory Interstitial Lung Disease

May 21, 2023

09:00 - 11:00

A 1044

Mini Symposium A17.

 

Tell me What You See: New Studies In Lung Imaging

 

Walter E. Washington Convention Center, Room 204 A-C (Level 2)

 

Dynamic Changes in Hyperpolarized 129Xe MRI Measures After Initiation of Therapy in Patients With Idiopathic Pulmonary Fibrosis Associate With Lung Function

 

 

May 21, 2023

Poster Viewing Time

09:00 - 09:45

Poster Discussion Time

09:45 - 11:00

 

823

Poster Discussion Session. A23.

 

LEVERAGING IMAGING AND BIOSAMPLES TO IMPROVE DIAGNOSIS AND RISK PREDICTION IN ILA AND ILD

 

Walter E. Washington Convention Center, Room 209 A-C (Level2)

Dynamic 129Xe-Hyperpolarized MRI for Non-invasive Evaluation of Regional Lung Ventilation in Thoracic Insufficiency Syndrome

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P508

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Retrospective Cardiopulmonary Gating of Free-breathing Hyperpolarized Xenon-129 Spectroscopy

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P511

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Assessing Unilateral Lung Transplantation With Dynamic Hyperpolarized Xenon-129

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P512

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Uneven Respiratory Function Observed With Dynamic Hyperpolarized Xenon-129 MRI in a Pig Thoracic Insufficiency Syndrome Model

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P513

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Feasibility of 3D Dynamic Gas- and Dissolved-Phase Imaging of the Rodent Lung Using Hyperpolarized 129Xe Magnetic Resonance Imaging

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P527

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Lung Structure-function in Pediatric Survivors of Congenital Diaphragmatic Hernia

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P528

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Measuring Lung Function With Inversion Instead of Saturation Recovery Hyperpolarized Xenon-129 MR Spectroscopy

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P529

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Minimal Clinically Important Difference for 129Xe MRI Ventilation Defect Percent in Patients With Asthma

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P538

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Hyperpolarized 129Xe Ventilation and Gas Exchange MRI in Young Adults With Cystic Fibrosis

May 21, 2023

Poster Viewing Time

11:30 - 13:15

P539

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Hyperpolarized 129-Xenon Magnetic Resonance Imaging (MRI) Ventilation Mapping in Pediatric COVID-19 Survivors

May 22, 2023

Poster Viewing Time

09:00 - 09:45

Poster Discussion Time

09:45 - 11:00

 

206

RAPiD: Rapid Abstract Poster Discussion Session. B27.

 

EVOLVING CONCEPTS IN LUNG FUNCTION TESTING AND MONITORING

 

Walter E. Washington Convention Center, Room 103 A-B (Street Level)

Tracking Regional Changes in CF Lung Disease After 1 Day of Airway-clearance Withdrawal, Using UTE and Xe MRI

May 23, 2023

Poster Viewing Time

14:15 - 15:00

Poster Discussion Time

15:00 - 16:15

 


Poster Discussion Session. C106.

 

OUT OF THE 'MUC': UPDATES IN PCD AND CF

 

Marriott Marquis Washington, Marquis Ballroom, Salons 3-4 (Level M2)

129Xe Magnetic Resonance Imaging-based Phenotypes of Long COVID: A Multi-center Evaluation

 May 24, 2023

Poster Viewing Time

12:00 - 12:45

Poster Discussion Time

12:45 - 14:00

 

602

Poster Discussion Session. D109.

 

THE LONG AND THE SHORT OF LONG COVID

 

Walter E. Washington Convention Center, Room 201 (Level 2) 

Post-acute COVID-19 Imaging Abnormalities on Hyperpolarized 129Xe MRI Persist Over 6 Months

May 24, 2023

Poster Viewing Time

12:00 - 12:45

Poster Discussion Time

12:45 - 14:00

 

610

Poster Discussion Session. D109.

 

THE LONG AND THE SHORT OF LONG COVID

 

Walter E. Washington Convention Center, Room 201 (Level 2)

 

Assessment of Gas Exchange in Long COVID Using Hyperpolarized 129-Xenon MRI and Dual Energy CT

May 23, 2023

Poster Viewing Time

12:00 - 12:45

Poster Discussion Time

12:45 - 14:00

 

611

Poster Discussion Session. D109.

 

THE LONG AND THE SHORT OF LONG COVID

 

Walter E. Washington Convention Center, Room 201 (Level 2)

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

Load more comments
Comment by from

2021

Featured at 2023 ATS Respiratory Innovation Summit

May 3, 2023, 16:29 by vivienne.seymour

Polarean also exhibiting at 2023 American Thoracic Society annual meeting, providing a great opportunity to showcase XENOVIEW technology to other pulmonary care innovators and providers

Polarean Imaging plc (AIM: POLX), the medical imaging technology company, has been selected as one of the featured companies as a poster presenter at the American Thoracic Society's ("ATS") 2023 Respiratory Innovation Summit ("RIS"), taking place 19-20 May in Washington D.C.

The Respiratory Innovation Summit unites innovators, investors, clinicians, and advocacy groups who work in the field of pulmonary medicine. The meeting historically attracts more than 275 global leaders representing all facets of the respiratory industry, including start-ups, venture capital, government, academia, and clinicians.

In addition to Polarean being selected as a featured company, Bastiaan Driehuys, PhD, Polarean's Chief Scientific Officer, will speak on lung imaging as a panel member in the "Biomarkers and Innovation" session taking place in the afternoon of 20 May at RIS.

Following the Respiratory Innovation Summit, Polarean will be exhibiting at the 2023 ATS International Conference, taking place 21-24 May. Polarean team members, including Bastiaan Driehuys, PhD (Chief Scientific Officer), and Alex Dusek (Chief Commercial Officer) will be onsite to provide information on the technology and also for networking.  Polarean can be found at booth # 2137.

The ATS International Conference connects specialists in all aspects of respiratory health - from clinicians to researchers to educators, all of whom share a passion for improving patient care. The conference showcases the latest advances and discoveries in respiratory science, patient care, and global public health.

Richard Hullihen, CEO of Polarean, said: "The Respiratory Innovation Summit and the American Thoracic Society's annual conference provide a great venue to showcase  XENOVIEW and the Xe MRI platform with individuals interested in the opportunities to collaborate. By creating greater awareness of our Xe MRI platform amongst clinicians, regulators, investors, and potential pharma industry partners, these events will be another step in advancing our commercialization strategy by growing awareness and interest in the different ways that our technology can move pulmonary care forward."

Additionally, at ATS numerous clinicians and scientists will be presenting on various research applications of Xe MRI.  A listing of these presentations, their title, author, and session time is available below.

Enquiries:

Polarean Imaging plc 

www.polarean.com / www.polarean-ir.com  

 Richard Hullihen, Chief Executive Officer 

Via Walbrook PR 

 Kenneth West, Chairman 




 Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker) 

+44 (0)20 7710 7600 

 Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking) 


 Nick Adams / Nick Harland (Corporate Broking) 



 Walbrook PR 

Tel: +44 (0)20 7933 8780 or [email protected]  

 Anna Dunphy / Phillip Marriage  

Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082 

RLF Communications (US media enquiries)
Michelle Rash

[email protected]
336-823-5501









About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical imaging technology companies operating in the high-resolution medical imaging space. Polarean aspires to revolutionize pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community in need of new solutions to evaluate lung ventilation, diagnose disease, characterize disease progression, and monitor response to treatment. By researching, developing, and commercializing novel imaging solutions with a non-invasive and radiation-free functional imaging platform. Polarean's vision is to help address the global unmet medical needs of more than 500 million patients worldwide suffering with chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized MRI contrast agent to be approved in the United States. On Dec. 23, 2022, the FDA granted approval for Polarean's first drug device combination product, XENOVIEWTM (Xenon Xe129 hyperpolarized). Xe129 MRI is also currently being studied for visualization and quantification of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream for future clinical indications.

About The American Thoracic Society (www.thoracic.org)

The American Thoracic Society (ATS) improves global health by advancing research, patient care, and public health in pulmonary disease, critical illness, and sleep disorders. Founded in 1905 to combat TB, the ATS has grown to tackle asthma, COPD, lung cancer, sepsis, acute respiratory distress, and sleep apnea, among other diseases.

XENOVIEW IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold.

Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated.

Adverse Reactions

Adverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness.  Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarized xenon Xe 129 administration. XENOVIEW is not approved for use in pediatric patients less than 12 years of age.

Please see full prescribing information at www.xenoview.net

 

ATS Abstract Title


  Presentation Date


 Abstract  Number


 Session and Location


129Xe Gas-exchange MRI and CT Pulmonary Vascular Abnormalities in GINA 4-5 Asthma

May 21, 2023

09:00 - 11:00

A 1043

Mini Symposium A17.

 

Tell me What You See: New Studies In Lung Imaging

 

Walter E. Washington Convention Center, Room 204 A-C (Level 2)

 

Hyperpolarized 129Xe MRI Visualizes Lung Function Impairment in Suspected Inflammatory Interstitial Lung Disease

May 21, 2023

09:00 - 11:00

A 1044

Mini Symposium A17.

 

Tell me What You See: New Studies In Lung Imaging

 

Walter E. Washington Convention Center, Room 204 A-C (Level 2)

 

Dynamic Changes in Hyperpolarized 129Xe MRI Measures After Initiation of Therapy in Patients With Idiopathic Pulmonary Fibrosis Associate With Lung Function

 

 

May 21, 2023

Poster Viewing Time

09:00 - 09:45

Poster Discussion Time

09:45 - 11:00

 

823

Poster Discussion Session. A23.

 

LEVERAGING IMAGING AND BIOSAMPLES TO IMPROVE DIAGNOSIS AND RISK PREDICTION IN ILA AND ILD

 

Walter E. Washington Convention Center, Room 209 A-C (Level2)

Dynamic 129Xe-Hyperpolarized MRI for Non-invasive Evaluation of Regional Lung Ventilation in Thoracic Insufficiency Syndrome

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P508

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Retrospective Cardiopulmonary Gating of Free-breathing Hyperpolarized Xenon-129 Spectroscopy

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P511

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Assessing Unilateral Lung Transplantation With Dynamic Hyperpolarized Xenon-129

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P512

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Uneven Respiratory Function Observed With Dynamic Hyperpolarized Xenon-129 MRI in a Pig Thoracic Insufficiency Syndrome Model

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P513

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Feasibility of 3D Dynamic Gas- and Dissolved-Phase Imaging of the Rodent Lung Using Hyperpolarized 129Xe Magnetic Resonance Imaging

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P527

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Lung Structure-function in Pediatric Survivors of Congenital Diaphragmatic Hernia

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P528

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Measuring Lung Function With Inversion Instead of Saturation Recovery Hyperpolarized Xenon-129 MR Spectroscopy

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P529

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Minimal Clinically Important Difference for 129Xe MRI Ventilation Defect Percent in Patients With Asthma

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P538

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Hyperpolarized 129Xe Ventilation and Gas Exchange MRI in Young Adults With Cystic Fibrosis

May 21, 2023

Poster Viewing Time

11:30 - 13:15

P539

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Hyperpolarized 129-Xenon Magnetic Resonance Imaging (MRI) Ventilation Mapping in Pediatric COVID-19 Survivors

May 22, 2023

Poster Viewing Time

09:00 - 09:45

Poster Discussion Time

09:45 - 11:00

 

206

RAPiD: Rapid Abstract Poster Discussion Session. B27.

 

EVOLVING CONCEPTS IN LUNG FUNCTION TESTING AND MONITORING

 

Walter E. Washington Convention Center, Room 103 A-B (Street Level)

Tracking Regional Changes in CF Lung Disease After 1 Day of Airway-clearance Withdrawal, Using UTE and Xe MRI

May 23, 2023

Poster Viewing Time

14:15 - 15:00

Poster Discussion Time

15:00 - 16:15

 


Poster Discussion Session. C106.

 

OUT OF THE 'MUC': UPDATES IN PCD AND CF

 

Marriott Marquis Washington, Marquis Ballroom, Salons 3-4 (Level M2)

129Xe Magnetic Resonance Imaging-based Phenotypes of Long COVID: A Multi-center Evaluation

 May 24, 2023

Poster Viewing Time

12:00 - 12:45

Poster Discussion Time

12:45 - 14:00

 

602

Poster Discussion Session. D109.

 

THE LONG AND THE SHORT OF LONG COVID

 

Walter E. Washington Convention Center, Room 201 (Level 2) 

Post-acute COVID-19 Imaging Abnormalities on Hyperpolarized 129Xe MRI Persist Over 6 Months

May 24, 2023

Poster Viewing Time

12:00 - 12:45

Poster Discussion Time

12:45 - 14:00

 

610

Poster Discussion Session. D109.

 

THE LONG AND THE SHORT OF LONG COVID

 

Walter E. Washington Convention Center, Room 201 (Level 2)

 

Assessment of Gas Exchange in Long COVID Using Hyperpolarized 129-Xenon MRI and Dual Energy CT

May 23, 2023

Poster Viewing Time

12:00 - 12:45

Poster Discussion Time

12:45 - 14:00

 

611

Poster Discussion Session. D109.

 

THE LONG AND THE SHORT OF LONG COVID

 

Walter E. Washington Convention Center, Room 201 (Level 2)

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

Load more comments
Comment by from

2020

Featured at 2023 ATS Respiratory Innovation Summit

May 3, 2023, 16:29 by vivienne.seymour

Polarean also exhibiting at 2023 American Thoracic Society annual meeting, providing a great opportunity to showcase XENOVIEW technology to other pulmonary care innovators and providers

Polarean Imaging plc (AIM: POLX), the medical imaging technology company, has been selected as one of the featured companies as a poster presenter at the American Thoracic Society's ("ATS") 2023 Respiratory Innovation Summit ("RIS"), taking place 19-20 May in Washington D.C.

The Respiratory Innovation Summit unites innovators, investors, clinicians, and advocacy groups who work in the field of pulmonary medicine. The meeting historically attracts more than 275 global leaders representing all facets of the respiratory industry, including start-ups, venture capital, government, academia, and clinicians.

In addition to Polarean being selected as a featured company, Bastiaan Driehuys, PhD, Polarean's Chief Scientific Officer, will speak on lung imaging as a panel member in the "Biomarkers and Innovation" session taking place in the afternoon of 20 May at RIS.

Following the Respiratory Innovation Summit, Polarean will be exhibiting at the 2023 ATS International Conference, taking place 21-24 May. Polarean team members, including Bastiaan Driehuys, PhD (Chief Scientific Officer), and Alex Dusek (Chief Commercial Officer) will be onsite to provide information on the technology and also for networking.  Polarean can be found at booth # 2137.

The ATS International Conference connects specialists in all aspects of respiratory health - from clinicians to researchers to educators, all of whom share a passion for improving patient care. The conference showcases the latest advances and discoveries in respiratory science, patient care, and global public health.

Richard Hullihen, CEO of Polarean, said: "The Respiratory Innovation Summit and the American Thoracic Society's annual conference provide a great venue to showcase  XENOVIEW and the Xe MRI platform with individuals interested in the opportunities to collaborate. By creating greater awareness of our Xe MRI platform amongst clinicians, regulators, investors, and potential pharma industry partners, these events will be another step in advancing our commercialization strategy by growing awareness and interest in the different ways that our technology can move pulmonary care forward."

Additionally, at ATS numerous clinicians and scientists will be presenting on various research applications of Xe MRI.  A listing of these presentations, their title, author, and session time is available below.

Enquiries:

Polarean Imaging plc 

www.polarean.com / www.polarean-ir.com  

 Richard Hullihen, Chief Executive Officer 

Via Walbrook PR 

 Kenneth West, Chairman 




 Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker) 

+44 (0)20 7710 7600 

 Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking) 


 Nick Adams / Nick Harland (Corporate Broking) 



 Walbrook PR 

Tel: +44 (0)20 7933 8780 or [email protected]  

 Anna Dunphy / Phillip Marriage  

Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082 

RLF Communications (US media enquiries)
Michelle Rash

[email protected]
336-823-5501









About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical imaging technology companies operating in the high-resolution medical imaging space. Polarean aspires to revolutionize pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community in need of new solutions to evaluate lung ventilation, diagnose disease, characterize disease progression, and monitor response to treatment. By researching, developing, and commercializing novel imaging solutions with a non-invasive and radiation-free functional imaging platform. Polarean's vision is to help address the global unmet medical needs of more than 500 million patients worldwide suffering with chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized MRI contrast agent to be approved in the United States. On Dec. 23, 2022, the FDA granted approval for Polarean's first drug device combination product, XENOVIEWTM (Xenon Xe129 hyperpolarized). Xe129 MRI is also currently being studied for visualization and quantification of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream for future clinical indications.

About The American Thoracic Society (www.thoracic.org)

The American Thoracic Society (ATS) improves global health by advancing research, patient care, and public health in pulmonary disease, critical illness, and sleep disorders. Founded in 1905 to combat TB, the ATS has grown to tackle asthma, COPD, lung cancer, sepsis, acute respiratory distress, and sleep apnea, among other diseases.

XENOVIEW IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold.

Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated.

Adverse Reactions

Adverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness.  Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarized xenon Xe 129 administration. XENOVIEW is not approved for use in pediatric patients less than 12 years of age.

Please see full prescribing information at www.xenoview.net

 

ATS Abstract Title


  Presentation Date


 Abstract  Number


 Session and Location


129Xe Gas-exchange MRI and CT Pulmonary Vascular Abnormalities in GINA 4-5 Asthma

May 21, 2023

09:00 - 11:00

A 1043

Mini Symposium A17.

 

Tell me What You See: New Studies In Lung Imaging

 

Walter E. Washington Convention Center, Room 204 A-C (Level 2)

 

Hyperpolarized 129Xe MRI Visualizes Lung Function Impairment in Suspected Inflammatory Interstitial Lung Disease

May 21, 2023

09:00 - 11:00

A 1044

Mini Symposium A17.

 

Tell me What You See: New Studies In Lung Imaging

 

Walter E. Washington Convention Center, Room 204 A-C (Level 2)

 

Dynamic Changes in Hyperpolarized 129Xe MRI Measures After Initiation of Therapy in Patients With Idiopathic Pulmonary Fibrosis Associate With Lung Function

 

 

May 21, 2023

Poster Viewing Time

09:00 - 09:45

Poster Discussion Time

09:45 - 11:00

 

823

Poster Discussion Session. A23.

 

LEVERAGING IMAGING AND BIOSAMPLES TO IMPROVE DIAGNOSIS AND RISK PREDICTION IN ILA AND ILD

 

Walter E. Washington Convention Center, Room 209 A-C (Level2)

Dynamic 129Xe-Hyperpolarized MRI for Non-invasive Evaluation of Regional Lung Ventilation in Thoracic Insufficiency Syndrome

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P508

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Retrospective Cardiopulmonary Gating of Free-breathing Hyperpolarized Xenon-129 Spectroscopy

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P511

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Assessing Unilateral Lung Transplantation With Dynamic Hyperpolarized Xenon-129

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P512

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Uneven Respiratory Function Observed With Dynamic Hyperpolarized Xenon-129 MRI in a Pig Thoracic Insufficiency Syndrome Model

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P513

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Feasibility of 3D Dynamic Gas- and Dissolved-Phase Imaging of the Rodent Lung Using Hyperpolarized 129Xe Magnetic Resonance Imaging

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P527

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Lung Structure-function in Pediatric Survivors of Congenital Diaphragmatic Hernia

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P528

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Measuring Lung Function With Inversion Instead of Saturation Recovery Hyperpolarized Xenon-129 MR Spectroscopy

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P529

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Minimal Clinically Important Difference for 129Xe MRI Ventilation Defect Percent in Patients With Asthma

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P538

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Hyperpolarized 129Xe Ventilation and Gas Exchange MRI in Young Adults With Cystic Fibrosis

May 21, 2023

Poster Viewing Time

11:30 - 13:15

P539

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Hyperpolarized 129-Xenon Magnetic Resonance Imaging (MRI) Ventilation Mapping in Pediatric COVID-19 Survivors

May 22, 2023

Poster Viewing Time

09:00 - 09:45

Poster Discussion Time

09:45 - 11:00

 

206

RAPiD: Rapid Abstract Poster Discussion Session. B27.

 

EVOLVING CONCEPTS IN LUNG FUNCTION TESTING AND MONITORING

 

Walter E. Washington Convention Center, Room 103 A-B (Street Level)

Tracking Regional Changes in CF Lung Disease After 1 Day of Airway-clearance Withdrawal, Using UTE and Xe MRI

May 23, 2023

Poster Viewing Time

14:15 - 15:00

Poster Discussion Time

15:00 - 16:15

 


Poster Discussion Session. C106.

 

OUT OF THE 'MUC': UPDATES IN PCD AND CF

 

Marriott Marquis Washington, Marquis Ballroom, Salons 3-4 (Level M2)

129Xe Magnetic Resonance Imaging-based Phenotypes of Long COVID: A Multi-center Evaluation

 May 24, 2023

Poster Viewing Time

12:00 - 12:45

Poster Discussion Time

12:45 - 14:00

 

602

Poster Discussion Session. D109.

 

THE LONG AND THE SHORT OF LONG COVID

 

Walter E. Washington Convention Center, Room 201 (Level 2) 

Post-acute COVID-19 Imaging Abnormalities on Hyperpolarized 129Xe MRI Persist Over 6 Months

May 24, 2023

Poster Viewing Time

12:00 - 12:45

Poster Discussion Time

12:45 - 14:00

 

610

Poster Discussion Session. D109.

 

THE LONG AND THE SHORT OF LONG COVID

 

Walter E. Washington Convention Center, Room 201 (Level 2)

 

Assessment of Gas Exchange in Long COVID Using Hyperpolarized 129-Xenon MRI and Dual Energy CT

May 23, 2023

Poster Viewing Time

12:00 - 12:45

Poster Discussion Time

12:45 - 14:00

 

611

Poster Discussion Session. D109.

 

THE LONG AND THE SHORT OF LONG COVID

 

Walter E. Washington Convention Center, Room 201 (Level 2)

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

Load more comments
Comment by from

2019

Featured at 2023 ATS Respiratory Innovation Summit

03 May 2023

Polarean also exhibiting at 2023 American Thoracic Society annual meeting, providing a great opportunity to showcase XENOVIEW technology to other pulmonary care innovators and providers

Polarean Imaging plc (AIM: POLX), the medical imaging technology company, has been selected as one of the featured companies as a poster presenter at the American Thoracic Society's ("ATS") 2023 Respiratory Innovation Summit ("RIS"), taking place 19-20 May in Washington D.C.

The Respiratory Innovation Summit unites innovators, investors, clinicians, and advocacy groups who work in the field of pulmonary medicine. The meeting historically attracts more than 275 global leaders representing all facets of the respiratory industry, including start-ups, venture capital, government, academia, and clinicians.

In addition to Polarean being selected as a featured company, Bastiaan Driehuys, PhD, Polarean's Chief Scientific Officer, will speak on lung imaging as a panel member in the "Biomarkers and Innovation" session taking place in the afternoon of 20 May at RIS.

Following the Respiratory Innovation Summit, Polarean will be exhibiting at the 2023 ATS International Conference, taking place 21-24 May. Polarean team members, including Bastiaan Driehuys, PhD (Chief Scientific Officer), and Alex Dusek (Chief Commercial Officer) will be onsite to provide information on the technology and also for networking.  Polarean can be found at booth # 2137.

The ATS International Conference connects specialists in all aspects of respiratory health - from clinicians to researchers to educators, all of whom share a passion for improving patient care. The conference showcases the latest advances and discoveries in respiratory science, patient care, and global public health.

Richard Hullihen, CEO of Polarean, said: "The Respiratory Innovation Summit and the American Thoracic Society's annual conference provide a great venue to showcase  XENOVIEW and the Xe MRI platform with individuals interested in the opportunities to collaborate. By creating greater awareness of our Xe MRI platform amongst clinicians, regulators, investors, and potential pharma industry partners, these events will be another step in advancing our commercialization strategy by growing awareness and interest in the different ways that our technology can move pulmonary care forward."

Additionally, at ATS numerous clinicians and scientists will be presenting on various research applications of Xe MRI.  A listing of these presentations, their title, author, and session time is available below.

Enquiries:

Polarean Imaging plc 

www.polarean.com / www.polarean-ir.com  

 Richard Hullihen, Chief Executive Officer 

Via Walbrook PR 

 Kenneth West, Chairman 




 Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker) 

+44 (0)20 7710 7600 

 Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking) 


 Nick Adams / Nick Harland (Corporate Broking) 



 Walbrook PR 

Tel: +44 (0)20 7933 8780 or [email protected]  

 Anna Dunphy / Phillip Marriage  

Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082 

RLF Communications (US media enquiries)
Michelle Rash

[email protected]
336-823-5501









About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical imaging technology companies operating in the high-resolution medical imaging space. Polarean aspires to revolutionize pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community in need of new solutions to evaluate lung ventilation, diagnose disease, characterize disease progression, and monitor response to treatment. By researching, developing, and commercializing novel imaging solutions with a non-invasive and radiation-free functional imaging platform. Polarean's vision is to help address the global unmet medical needs of more than 500 million patients worldwide suffering with chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized MRI contrast agent to be approved in the United States. On Dec. 23, 2022, the FDA granted approval for Polarean's first drug device combination product, XENOVIEWTM (Xenon Xe129 hyperpolarized). Xe129 MRI is also currently being studied for visualization and quantification of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream for future clinical indications.

About The American Thoracic Society (www.thoracic.org)

The American Thoracic Society (ATS) improves global health by advancing research, patient care, and public health in pulmonary disease, critical illness, and sleep disorders. Founded in 1905 to combat TB, the ATS has grown to tackle asthma, COPD, lung cancer, sepsis, acute respiratory distress, and sleep apnea, among other diseases.

XENOVIEW IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold.

Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated.

Adverse Reactions

Adverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness.  Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarized xenon Xe 129 administration. XENOVIEW is not approved for use in pediatric patients less than 12 years of age.

Please see full prescribing information at www.xenoview.net

 

ATS Abstract Title


  Presentation Date


 Abstract  Number


 Session and Location


129Xe Gas-exchange MRI and CT Pulmonary Vascular Abnormalities in GINA 4-5 Asthma

May 21, 2023

09:00 - 11:00

A 1043

Mini Symposium A17.

 

Tell me What You See: New Studies In Lung Imaging

 

Walter E. Washington Convention Center, Room 204 A-C (Level 2)

 

Hyperpolarized 129Xe MRI Visualizes Lung Function Impairment in Suspected Inflammatory Interstitial Lung Disease

May 21, 2023

09:00 - 11:00

A 1044

Mini Symposium A17.

 

Tell me What You See: New Studies In Lung Imaging

 

Walter E. Washington Convention Center, Room 204 A-C (Level 2)

 

Dynamic Changes in Hyperpolarized 129Xe MRI Measures After Initiation of Therapy in Patients With Idiopathic Pulmonary Fibrosis Associate With Lung Function

 

 

May 21, 2023

Poster Viewing Time

09:00 - 09:45

Poster Discussion Time

09:45 - 11:00

 

823

Poster Discussion Session. A23.

 

LEVERAGING IMAGING AND BIOSAMPLES TO IMPROVE DIAGNOSIS AND RISK PREDICTION IN ILA AND ILD

 

Walter E. Washington Convention Center, Room 209 A-C (Level2)

Dynamic 129Xe-Hyperpolarized MRI for Non-invasive Evaluation of Regional Lung Ventilation in Thoracic Insufficiency Syndrome

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P508

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Retrospective Cardiopulmonary Gating of Free-breathing Hyperpolarized Xenon-129 Spectroscopy

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P511

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Assessing Unilateral Lung Transplantation With Dynamic Hyperpolarized Xenon-129

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P512

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Uneven Respiratory Function Observed With Dynamic Hyperpolarized Xenon-129 MRI in a Pig Thoracic Insufficiency Syndrome Model

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P513

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Feasibility of 3D Dynamic Gas- and Dissolved-Phase Imaging of the Rodent Lung Using Hyperpolarized 129Xe Magnetic Resonance Imaging

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P527

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Lung Structure-function in Pediatric Survivors of Congenital Diaphragmatic Hernia

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P528

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Measuring Lung Function With Inversion Instead of Saturation Recovery Hyperpolarized Xenon-129 MR Spectroscopy

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P529

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Minimal Clinically Important Difference for 129Xe MRI Ventilation Defect Percent in Patients With Asthma

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P538

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Hyperpolarized 129Xe Ventilation and Gas Exchange MRI in Young Adults With Cystic Fibrosis

May 21, 2023

Poster Viewing Time

11:30 - 13:15

P539

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Hyperpolarized 129-Xenon Magnetic Resonance Imaging (MRI) Ventilation Mapping in Pediatric COVID-19 Survivors

May 22, 2023

Poster Viewing Time

09:00 - 09:45

Poster Discussion Time

09:45 - 11:00

 

206

RAPiD: Rapid Abstract Poster Discussion Session. B27.

 

EVOLVING CONCEPTS IN LUNG FUNCTION TESTING AND MONITORING

 

Walter E. Washington Convention Center, Room 103 A-B (Street Level)

Tracking Regional Changes in CF Lung Disease After 1 Day of Airway-clearance Withdrawal, Using UTE and Xe MRI

May 23, 2023

Poster Viewing Time

14:15 - 15:00

Poster Discussion Time

15:00 - 16:15

 


Poster Discussion Session. C106.

 

OUT OF THE 'MUC': UPDATES IN PCD AND CF

 

Marriott Marquis Washington, Marquis Ballroom, Salons 3-4 (Level M2)

129Xe Magnetic Resonance Imaging-based Phenotypes of Long COVID: A Multi-center Evaluation

 May 24, 2023

Poster Viewing Time

12:00 - 12:45

Poster Discussion Time

12:45 - 14:00

 

602

Poster Discussion Session. D109.

 

THE LONG AND THE SHORT OF LONG COVID

 

Walter E. Washington Convention Center, Room 201 (Level 2) 

Post-acute COVID-19 Imaging Abnormalities on Hyperpolarized 129Xe MRI Persist Over 6 Months

May 24, 2023

Poster Viewing Time

12:00 - 12:45

Poster Discussion Time

12:45 - 14:00

 

610

Poster Discussion Session. D109.

 

THE LONG AND THE SHORT OF LONG COVID

 

Walter E. Washington Convention Center, Room 201 (Level 2)

 

Assessment of Gas Exchange in Long COVID Using Hyperpolarized 129-Xenon MRI and Dual Energy CT

May 23, 2023

Poster Viewing Time

12:00 - 12:45

Poster Discussion Time

12:45 - 14:00

 

611

Poster Discussion Session. D109.

 

THE LONG AND THE SHORT OF LONG COVID

 

Walter E. Washington Convention Center, Room 201 (Level 2)

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

2018

Featured at 2023 ATS Respiratory Innovation Summit

03 May 2023

Polarean also exhibiting at 2023 American Thoracic Society annual meeting, providing a great opportunity to showcase XENOVIEW technology to other pulmonary care innovators and providers

Polarean Imaging plc (AIM: POLX), the medical imaging technology company, has been selected as one of the featured companies as a poster presenter at the American Thoracic Society's ("ATS") 2023 Respiratory Innovation Summit ("RIS"), taking place 19-20 May in Washington D.C.

The Respiratory Innovation Summit unites innovators, investors, clinicians, and advocacy groups who work in the field of pulmonary medicine. The meeting historically attracts more than 275 global leaders representing all facets of the respiratory industry, including start-ups, venture capital, government, academia, and clinicians.

In addition to Polarean being selected as a featured company, Bastiaan Driehuys, PhD, Polarean's Chief Scientific Officer, will speak on lung imaging as a panel member in the "Biomarkers and Innovation" session taking place in the afternoon of 20 May at RIS.

Following the Respiratory Innovation Summit, Polarean will be exhibiting at the 2023 ATS International Conference, taking place 21-24 May. Polarean team members, including Bastiaan Driehuys, PhD (Chief Scientific Officer), and Alex Dusek (Chief Commercial Officer) will be onsite to provide information on the technology and also for networking.  Polarean can be found at booth # 2137.

The ATS International Conference connects specialists in all aspects of respiratory health - from clinicians to researchers to educators, all of whom share a passion for improving patient care. The conference showcases the latest advances and discoveries in respiratory science, patient care, and global public health.

Richard Hullihen, CEO of Polarean, said: "The Respiratory Innovation Summit and the American Thoracic Society's annual conference provide a great venue to showcase  XENOVIEW and the Xe MRI platform with individuals interested in the opportunities to collaborate. By creating greater awareness of our Xe MRI platform amongst clinicians, regulators, investors, and potential pharma industry partners, these events will be another step in advancing our commercialization strategy by growing awareness and interest in the different ways that our technology can move pulmonary care forward."

Additionally, at ATS numerous clinicians and scientists will be presenting on various research applications of Xe MRI.  A listing of these presentations, their title, author, and session time is available below.

Enquiries:

Polarean Imaging plc 

www.polarean.com / www.polarean-ir.com  

 Richard Hullihen, Chief Executive Officer 

Via Walbrook PR 

 Kenneth West, Chairman 




 Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker) 

+44 (0)20 7710 7600 

 Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking) 


 Nick Adams / Nick Harland (Corporate Broking) 



 Walbrook PR 

Tel: +44 (0)20 7933 8780 or [email protected]  

 Anna Dunphy / Phillip Marriage  

Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082 

RLF Communications (US media enquiries)
Michelle Rash

[email protected]
336-823-5501









About Polarean (www.polarean.com)

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical imaging technology companies operating in the high-resolution medical imaging space. Polarean aspires to revolutionize pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community in need of new solutions to evaluate lung ventilation, diagnose disease, characterize disease progression, and monitor response to treatment. By researching, developing, and commercializing novel imaging solutions with a non-invasive and radiation-free functional imaging platform. Polarean's vision is to help address the global unmet medical needs of more than 500 million patients worldwide suffering with chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized MRI contrast agent to be approved in the United States. On Dec. 23, 2022, the FDA granted approval for Polarean's first drug device combination product, XENOVIEWTM (Xenon Xe129 hyperpolarized). Xe129 MRI is also currently being studied for visualization and quantification of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream for future clinical indications.

About The American Thoracic Society (www.thoracic.org)

The American Thoracic Society (ATS) improves global health by advancing research, patient care, and public health in pulmonary disease, critical illness, and sleep disorders. Founded in 1905 to combat TB, the ATS has grown to tackle asthma, COPD, lung cancer, sepsis, acute respiratory distress, and sleep apnea, among other diseases.

XENOVIEW IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold.

Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated.

Adverse Reactions

Adverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness.  Adverse Reactions in Pediatric and Adolescent Patients: In published literature in pediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of pediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarized xenon Xe 129 administration. XENOVIEW is not approved for use in pediatric patients less than 12 years of age.

Please see full prescribing information at www.xenoview.net

 

ATS Abstract Title


  Presentation Date


 Abstract  Number


 Session and Location


129Xe Gas-exchange MRI and CT Pulmonary Vascular Abnormalities in GINA 4-5 Asthma

May 21, 2023

09:00 - 11:00

A 1043

Mini Symposium A17.

 

Tell me What You See: New Studies In Lung Imaging

 

Walter E. Washington Convention Center, Room 204 A-C (Level 2)

 

Hyperpolarized 129Xe MRI Visualizes Lung Function Impairment in Suspected Inflammatory Interstitial Lung Disease

May 21, 2023

09:00 - 11:00

A 1044

Mini Symposium A17.

 

Tell me What You See: New Studies In Lung Imaging

 

Walter E. Washington Convention Center, Room 204 A-C (Level 2)

 

Dynamic Changes in Hyperpolarized 129Xe MRI Measures After Initiation of Therapy in Patients With Idiopathic Pulmonary Fibrosis Associate With Lung Function

 

 

May 21, 2023

Poster Viewing Time

09:00 - 09:45

Poster Discussion Time

09:45 - 11:00

 

823

Poster Discussion Session. A23.

 

LEVERAGING IMAGING AND BIOSAMPLES TO IMPROVE DIAGNOSIS AND RISK PREDICTION IN ILA AND ILD

 

Walter E. Washington Convention Center, Room 209 A-C (Level2)

Dynamic 129Xe-Hyperpolarized MRI for Non-invasive Evaluation of Regional Lung Ventilation in Thoracic Insufficiency Syndrome

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P508

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Retrospective Cardiopulmonary Gating of Free-breathing Hyperpolarized Xenon-129 Spectroscopy

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P511

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Assessing Unilateral Lung Transplantation With Dynamic Hyperpolarized Xenon-129

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P512

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Uneven Respiratory Function Observed With Dynamic Hyperpolarized Xenon-129 MRI in a Pig Thoracic Insufficiency Syndrome Model

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P513

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Feasibility of 3D Dynamic Gas- and Dissolved-Phase Imaging of the Rodent Lung Using Hyperpolarized 129Xe Magnetic Resonance Imaging

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P527

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Lung Structure-function in Pediatric Survivors of Congenital Diaphragmatic Hernia

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P528

Thematic Poster Session. A69.

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Measuring Lung Function With Inversion Instead of Saturation Recovery Hyperpolarized Xenon-129 MR Spectroscopy

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P529

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Minimal Clinically Important Difference for 129Xe MRI Ventilation Defect Percent in Patients With Asthma

May 21, 2023

Poster Viewing Time

11:30 - 13:15

 

P538

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Hyperpolarized 129Xe Ventilation and Gas Exchange MRI in Young Adults With Cystic Fibrosis

May 21, 2023

Poster Viewing Time

11:30 - 13:15

P539

Thematic Poster Session. A69.

 

AN IMAGE'S WORTH: STUDIES IN LUNG IMAGING

 

Walter E. Washington Convention Center, Area E, Hall C (Lower Level)

Hyperpolarized 129-Xenon Magnetic Resonance Imaging (MRI) Ventilation Mapping in Pediatric COVID-19 Survivors

May 22, 2023

Poster Viewing Time

09:00 - 09:45

Poster Discussion Time

09:45 - 11:00

 

206

RAPiD: Rapid Abstract Poster Discussion Session. B27.

 

EVOLVING CONCEPTS IN LUNG FUNCTION TESTING AND MONITORING

 

Walter E. Washington Convention Center, Room 103 A-B (Street Level)

Tracking Regional Changes in CF Lung Disease After 1 Day of Airway-clearance Withdrawal, Using UTE and Xe MRI

May 23, 2023

Poster Viewing Time

14:15 - 15:00

Poster Discussion Time

15:00 - 16:15

 


Poster Discussion Session. C106.

 

OUT OF THE 'MUC': UPDATES IN PCD AND CF

 

Marriott Marquis Washington, Marquis Ballroom, Salons 3-4 (Level M2)

129Xe Magnetic Resonance Imaging-based Phenotypes of Long COVID: A Multi-center Evaluation

 May 24, 2023

Poster Viewing Time

12:00 - 12:45

Poster Discussion Time

12:45 - 14:00

 

602

Poster Discussion Session. D109.

 

THE LONG AND THE SHORT OF LONG COVID

 

Walter E. Washington Convention Center, Room 201 (Level 2) 

Post-acute COVID-19 Imaging Abnormalities on Hyperpolarized 129Xe MRI Persist Over 6 Months

May 24, 2023

Poster Viewing Time

12:00 - 12:45

Poster Discussion Time

12:45 - 14:00

 

610

Poster Discussion Session. D109.

 

THE LONG AND THE SHORT OF LONG COVID

 

Walter E. Washington Convention Center, Room 201 (Level 2)

 

Assessment of Gas Exchange in Long COVID Using Hyperpolarized 129-Xenon MRI and Dual Energy CT

May 23, 2023

Poster Viewing Time

12:00 - 12:45

Poster Discussion Time

12:45 - 14:00

 

611

Poster Discussion Session. D109.

 

THE LONG AND THE SHORT OF LONG COVID

 

Walter E. Washington Convention Center, Room 201 (Level 2)

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

Investor Alert

Sign up for Email Alerts